Skip to main content

Swiss Chinese Life Science Forum (EN)

ONSITE REGISTRATION

Fortunately we are already fully booked on site.

Please use the possibility of online participation.
Thank you very much.

The Rise of China’s Pharmaceutical Industry: Global Impact and Opportunities 

Switzerland is home to a highly innovative life sciences cluster. Many multinational corporations, as well as a network of smaller companies and startups have operations in Switzerland, mostly in the Basel Area. The industry is vibrant, with many innovative developments occurring in pharmaceuticals, biotech or digital health.  

In China, the life sciences industry has been growing at an accelerated pace in the last few years and at the same time China is moving towards becoming the largest pharmaceutical market in the world.  

Both, Swiss and Chinese companies have a lot to gain from innovation and international expansion.  

 

During this year’s Swiss Chinese Life Sciences Forum, we will address current key issues in the industry. Guest speakers from Swiss as well as Chinese companies will present insights into the following topics: 

  • Ways to set up operations in Switzerland to access the European market 
  • Innovation at startups 
  • Macro-economic trends in the life sciences industry and regulatory developments 
  • Strengthening Sino-Swiss collaboration  

We are looking forward to welcoming you at this year’s Life Sciences Forum! 

Program

09:00

Door Opening & Registration

09:30

Welcome
Mr. Daniel Brindle, Country President Novartis China

Ms. Beilun Wei, General Manager, Swiss Chinese Chamber of Commerce
Mr. Christian Wyss, Partner, VISCHER
Ms. Anke Hollnagel, Director Asia, Basel Area Business & Innovation

09:35

Introduction of panelists
Mr. Gabriel Schweizer, Moderator

09:40

Tough times for Chinese life sciences companies
Mr. Hubert Stadler, Partner, EY Consulting 

09:55

View on Europe through the eyes of Chinese biopharma company  
Ms. Ke YING; Global Head R&D collaboration, Shanghai Pharma

10:10

Bridging the gap of innovative neuroscience treatments between China and Switzerland
Mr. Thomas Meier, Executive Board Member, Novaremed/Neurofront
Mr. Tianke Wang, Dao Tun

10:25

Licensing – an effective way to access the Chinese market 
Ms. Yuehua Cong, Head of Europe Business Development & Licensing, Simcere 

10:40

Panel discussion

11:15

Closing
Ms. Beilun Wei, General Manager, Swiss Chinese Chamber of Commerce
Mr.  Christian Wyss, Partner, VISCHER
Ms. Anke Hollnagel, Director Asia, Basel Area Business & Innovation

11:20

Networking Lunch

12:30

End of event

Participation is free, however registration is required before 27. April 2023.

Our partners